Women’s Representation in CVD Drug Trials Varies
Representation of women is low for cardiovascular disease clinical trials in certain conditions.
Representation of women is low for cardiovascular disease clinical trials in certain conditions.
Nebulized glycopyrrolate improves lung function and patient-reported outcomes in patients with moderate to very severe COPD.
Idarucizumab can effectively reverse the anticoagulant effect of dabigatran.
Mexiletine significantly reduced life-threatening arrhythmic events in long QT syndrome type 3 patients.
Acute kidney injury occurred in 20.8% of the atorvastatin group and 19.5% of the placebo group, indicating that initiating perioperative statin therapy does not prevent AKI following cardiac surgery.
Researchers found that when oral beta-blockers were administered less than 24 hours after hospital admission, in-hospitality mortality and severe left ventricular dysfunction were both reduced.
N-3 polyunsaturated fatty acid use is associated with reduced risk of all-cause mortality and recurrent acute myocardial infarction.
Black patients may be less response to antihypertensive treatment with angiotensin-converting enzyme inhibitors than white patients.
Recent trials have shown that cryoballoon catheter ablation has demonstrated success in treating atrial fibrillation among 74% of patients, presenting an alternative to traditional radiofrequency ablation.
Intended to reduce risk of cardiovascular death and heart failure-related hospitalization, the FDA has approved Entresto.